Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive tracer could spot hidden cancers in ovarian, lung, and pancreatic tumors

NCT ID NCT06843629

Recruiting now Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy volunteers. The goal is to improve diagnosis and help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-NOTA-MSLN antibody fragment (a radioactive imaging agent)
What this could lead to
If successful, this could provide a more accurate way to detect and stage certain cancers, helping doctors choose the best treatment.
What could go wrong
This is an early-phase diagnostic study, not a treatment. The imaging agent may not prove more effective than current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung exocrine pancreatic carcinoma lung adenocarcinoma malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG ADENOCARCINOMA OVARIAN CANCER PANCREATIC CANCER

Contacts and locations

Locations

  • Wuhan Union Hospital, China

    RECRUITING

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.